Tai-Tsang Chen, Ph.D.

 Adjunct Assistant Professor of Biostatistics
Department of Biostatistics
Mailman School of Public Health
722 West 168th Street, 6th Floor
New York, NY 10032 USA
E-mail Address: tc195 AT cumc DOT columbia DOT edu
  ABOUT ME   RESEARCH INTERESTS
  Dr. Chen is a clinical trial researcher who specializes in biostatistics. Currently he is holding the position of Vice President heading up Biostatistics, Clinical Pharmacology and Pharmacometrics at Bristol-Myers Squibb Company. Dr. Chen was trained as a clinical psychologist and had worked in a psychiatric institute in Taiwan.     Immuno-Oncology trial design and analysis
    Pharmaceutical statistics
    Diagnostic procedure accuracy
    Group sequential design/analysis
    Innovative clinical trial design
    Causal inference
Affiliations

Vice President, Biostatistics, Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb Company
Member, American Society of Clinical Oncology (ASCO)
Associate Editor and Member, Society of Immunotherapy for Cancer (SITC)
Board member, Columbia University Mailman School of Public Health Alumni Association
  STUDY DESIGN TOOLS   MY PICTURE OF THE MONTH

Grand Central Station, NYC
  SELECT PUBLICATIONS
    Tai-Tsang Chen. (2018). Designing late-stage randomized clinical trials with cancer immunotherapy: can we make it simpler? Cancer Immunology Research, 6(3): 250-254.
    Stefan Suciu, Alexander M. M. Eggermont, Paul Lorigan, John M. Kirkwood, Svetomir N. Markovic, Claus Garbe, David Cameron, Srividya Kotapati, Tai-Tsang Chen, Keith Wheatley, Natalie Ives, Gaetan de Schaetzen, Achmad Efendi, Marc Buyse. (2018). Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. Journal of the National Cancer Institute, 110(1): djx133.
    Edward Korn, Megan Othus, Tai-Tsang Chen, Boris Freidlin. (2017). Assessing treatment efficacy in the subset of responders in a randomized clinical trial. Annals of Oncology, 28(7): 1640-1647.
    Neil Lineberry, Jesse A Berlin, Bernadette Mansi, Susan Glasser, Michael Berkwits, Christian Klem, Ananya Bhattacharya, Leslie Citrome, Robert Enck, John Fletcher, Daniel Haller, Tai-Tsang Chen, Christine Laine. (2016). Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. The British Medical Journal, 355:i5078.
    Justine E. Dickson, Whitney Y. Hung, Tai-Tsang Chen and Marjorie Golden. (2016). Clinical impact of probiotics among patients receiving antibiotics with a high risk of acquiring clostridium difficile infection. International Journal of Digestive Diseases, 2(1): 18.
    Tai-Tsang Chen. (2016). Predicting analysis times in randomized clinical trials with cancer immunotherapy. BMC Medical Research Methodology, 16: 12.
    Rosemarie Mick and Tai-Tsang Chen. (2015). Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies. Cancer Immunology Research, 3(12): 1292-1298.
    Tai-Tsang Chen. (2015). Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. Journal of the National Cancer Institute, 107(9): djv156.
    Tai-Tsang Chen. Statistical issues on the design and analysis of cancer immunotherapy trials. In American Association of Cancer Research Annual Meeting 2015 Education Book; 2015 April 18-22, Philadelphia, Pa., Philadelphia: AACR; 2015, p.107-110.
    Dirk Schadendorf, F. Stephen Hodi, Caroline Robert, Jeffrey S. Weber, Kim Margolin, Omid Hamid, Debra Patt, Tai-Tsang Chen, David M. Berman, and Jedd D. Wolchok. (2015). Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 33(17): 1889-1894.
    Michele Maio, Jean-Jacques Grob, Steinar Aamdal, Igor Bondarenko, Caroline Robert, Luc Thomas, Claus Garbe, Vanna Chiarion-Sileni, Alessandro Testori, Tai-Tsang Chen, Marina Tschaika, and Jedd D. Wolchok. (2015). Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. Journal of Clinical Oncology, 33(10): 1191-1196.
    Tai-Tsang Chen. (2013). Statistical Issues and Challenges in Immuno-Oncology. Journal for Immunotherapy of Cancer, 1:18.
    Jonathan Denne, Andrew Stone, Renee Iacona and Tai-Tsang Chen. (2013). Missing data and censoring in the analysis of progression-free survival in oncology clinical trials. Journal of Biopharmaceutical Statistics, 23(5), 951-970.
    Yan Feng, Amit Roy, Eric Masson, Tai-Tsang Chen, Rachel Humphrey & Jeffrey S. Weber. (2013). Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clinical Cancer Research, 19, 3977-3986.
    Xiaoning Wang, Amit Roy, Andreas Hochhaus, Hagop M Kantarjian, Tai-Tsang Chen, Neil P Shah. (2013). Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clinical Pharmacology: Advances and Applications, 5(1), 85-97.
    Caroline Robert, Luc Thomas, Igor Bondarenko, Steven O'Day Jeffrey Weber, Claus Garbe, Celeste Lebbe, Jean-Francois Baurain, Alessandro Testori, Jean-Jaques Grob, Neville Davidson, Jon Richards, Michele Maio, Axel Hauschild, Wilson Miller, Pere Gascon, Michal Lotem, Kaan Harmankaya, Ramy Ibrahim, Stephen Francis, Tai-Tsang Chen, Rachel Humphrey, Axel Hoos, Jedd Wolchok. (2011). Phase III study of ipilimumab plus dacarbazine as first line treatment in patients with unresectable stage III or IV melanoma. New England Journal of Medicine,, 364: 2517-2526.
    Jedd D. Wolchok, Jeffrey S. Weber, Omid Hamid, Celeste Lebb, Michele Maio, Dirk Schadendorf, Veerle de Pril, Kevin Heller, Tai-Tsang Chen, Ramy Ibrahim, Axel Hoos and Steven J. O'Day. (2010). Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLT subtype from four trials. Cancer Immunity, 10:9.
    Chen, Tai-Tsang & Anderson, Aparna. (2009). Novel Cancer Therapies: Issues to Consider in Designing Clinical Trials. Biopharmaceutial Report, 16(2), 4-10.
    Alfonso Quintás-Cardama, Jorge E. Cortes, Susan O'Brien, Farhad Ravandi, Gautam Borthakur, David Liu, Eric Bleickardt, Tai-Tsang Chen, Hagop M. Kantarjian. (2009). Dasatinib Early Intervention after Cytogenetic or Hematologic Resistance to Imatinib in Patients with Chronic Myeloid Leukemia. Cancer, 115(13), 2912-2921.
    Sinha, Ritwik, Chen, Tai-Tsang, & Zhu, Chao. (2008). Intent-to-Treat Duration of Response: Statistical Issues in Study Design and Analysis. Proceedings of the American Statistical Association, Biometrics Section [CD-ROM], Denver, CO: American Statistical Association: 964-968.
    Chen, Tai-Tsang, Iyer, Vishwanath, & Anderson, Aparna. (2007). Sample Size Determination for Binomial Endpoints Based on the Width of the Confidence Interval in Phase IIA Clinical Trials. Proceedings of the American Statistical Association, Biopharmaceutical Section [CD-ROM], Salt Lake City, UT: American Statistical Association: 808-812.
    Moshe Talpaz*, Neil P. Shah, Hagop Kantarjian, Nicholas Donato, John Nicoll, Ron Paquette, Jorge Cortes, Susan O'Brien, Claude Nicaise, Eric Bleickardt, M. Anne Blackwood-Chirchir, Vishwanath Iyer, Tai-Tsang Chen, Fei Huang, Arthur P. Decillis, Charles L. Sawyers (2006). Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 354(24), 2531-2541.
    Ying, Gui-Shuang, Heitjan, Daniel F., & Chen, Tai-Tsang. (2004). Nonparametric Prediction of Analysis Times in Randomized Clinical Trials. Clinical Trials, 1(4), 352-361.
    Miller KD, Saphner T, Waterhouse D, Chen Tai-Tsang, Rush-Taylor A, Sparano J, Wolff A, Cobleigh M, Galbraith S and Sledge GW. (2004). A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer. Clinical Cancer Research, 10, 1971-1975.